Oriol Mirallas - Publications

Novel Immunotherapy Agents in Early-Phase Trials for Head and Neck Cancer.

Journal: JAMA network open

Published: July 16, 2026

Liquid biopsy in oncology practice: A global survey by the Young Committee of the International Society of Liquid Biopsy (ISLB).

Journal: The journal of liquid biopsy

Published: June 19, 2026

Clinical determinants of survival outcomes and acute toxicity after adoptive cellular therapy for solid tumors.

Journal: Frontiers in immunology

Published: April 06, 2026

"SMAC"-down for the apoptosis-restoring drug, Xevinapant: What does its story reveal?

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 14, 2026

Targeting claudins in gastric cancer: A novel GLOWing strategy in the SPOTLIGHT.

Journal: Cancer treatment reviews

Published: February 24, 2026

Targeting Regulatory T Cells for Cancer Immunotherapy: Promises and Pitfalls.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 26, 2026

Targeting regulatory T cells for cancer immunotherapy: promises and pitfalls.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 26, 2026

Immune phenotype and RAS/BRAF status predict outcomes after lung metastasectomy for colorectal cancer.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: January 13, 2026

Evolving landscape of targeted therapies in early phase clinical trials.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 04, 2026

Integrating C-reactive protein flare and early MRI dynamics for enhanced prediction of immunotherapy response.

Journal: Journal for immunotherapy of cancer

Published: November 30, 2025

Somatic copy number alterations profiling in non-small cell lung cancer and their correlation with clinical efficacy in first-line treatment.

Journal: Genome medicine

Published: November 07, 2025

Second-event endpoints (EFS2, PRFS2 and PFS2) after anti-PD-(L)1-based RCTs: a systematic review and meta-analysis.

Journal: Journal for immunotherapy of cancer

Published: November 07, 2025